A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
NCT01848561 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 8250
Last updated 2025-07-16
Summary
This is a registry study to evaluate the long-term safety and effectiveness of adalimumab in patients with moderately to severely active UC who are treated as recommended in the product label.
Conditions
- Ulcerative Colitis (UC)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
ABBVIE INC. · AbbVie
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-04-29
- Primary Completion
- 2028-06-30
- Completion
- 2028-06-30
Countries
- United States
- Australia
- Austria
- Belgium
- Canada
- Croatia
- Denmark
- France
- Germany
- Greece
- Ireland
- Israel
- Italy
- Mexico
- Netherlands
- New Zealand
- Norway
- Puerto Rico
- Spain
- Sweden
- United Kingdom
Study Locations
More Related Trials
-
Effectiveness and Safety in Patients With Crohn´s Disease in Clinical Routine
NCT01083680 ·Status: COMPLETED
-
A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn's Disease (CD)
NCT02130362 ·Status: ACTIVE_NOT_RECRUITING
-
Open Label Study to Evaluate Long Term Efficacy, Safety and Tolerability of Repeated Dosing in Subjects With Crohn's Disease and Who Participated and Successfully Completed M14-115
NCT02185014 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
NCT00409617 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
NCT05394805 ·Status: COMPLETED
-
Study of the Efficacy and Safety of AMT-101 in Combination With Adalimumab in Subjects With Ulcerative Colitis (MARKET)
NCT05372939 ·Status: COMPLETED ·Phase: PHASE2
-
Adalimumab in the Treatment of Chronic Pouchitis
NCT01670240 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis
NCT00385736 ·Status: COMPLETED ·Phase: PHASE3
-
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
NCT01960790 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis
NCT02065557 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis
NCT02632175 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Outcome After Escalation and De-escalation of Adalimumab in Real Life in Ulcerative Colitis
NCT03142113 ·Status: COMPLETED
-
Efficacy and Safety of Adalimumab for the Induction of Clinical Response in Ulcerative Colitis
NCT01494857 ·Status: UNKNOWN ·Phase: PHASE3
-
A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice
NCT02499263 ·Status: COMPLETED
-
Human Anti-TNF Monoclonal Antibody Adalimumab in Canadian Subjects With Moderate to Severe Crohn's Disease (ACCESS)
NCT00427921 ·Status: COMPLETED ·Phase: PHASE3
-
Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease
NCT00195715 ·Status: COMPLETED ·Phase: PHASE3
-
Open-Label Adalimumab for Ulcerative Colitis Patients
NCT00421642 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
NCT00408629 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis
NCT06257875 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis
NCT00355901 ·Status: TERMINATED
-
Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study
NCT02450513 ·Status: COMPLETED
-
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
NCT02163759 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
NCT03464136 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab
NCT04183608 ·Status: RECRUITING ·Phase: PHASE4
-
An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
NCT05494606 ·Status: ACTIVE_NOT_RECRUITING